Market Cap 2.24B
Revenue (ttm) 14.00M
Net Income (ttm) -130.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -931.36%
Debt to Equity Ratio 12.75
Volume 2,211,500
Avg Vol 2,679,922
Day's Range N/A - N/A
Shares Out 86.09M
Stochastic %K 8%
Beta 0.22
Analysts Strong Sell
Price Target $36.70

Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneou...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 328 4400
Fax: 919 328 4402
Address:
419 Davis Drive, Suite 100, Morrisville, United States
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 6:55 PM
Enter: $LQDA OCT 17 2025 $28 CALLS Buy in Price: $2.55 - $2.75 Take Profit: $2.93 Stop Bleeding: $2.24 ROI Potential: 15% Exit Within: 64 Minutes https://moneygroup.us/alerts
0 · Reply
clan
clan Sep. 13 at 9:45 AM
$LQDA Filling the gap. Sell. Short. Buy puts. $SPY people react.
0 · Reply
stocksmanagement
stocksmanagement Sep. 12 at 7:26 PM
$LQDA will re bullish
0 · Reply
BullRun4
BullRun4 Sep. 12 at 7:11 PM
$LQDA Yutrepia is the clear WINNER with Pulmonologist for patients with PH-ILD! Liquidia is growing their business at a super fast rate. Sales are going very strong and next filing will demonstrate how quickly they have taken control of that patient segment.
2 · Reply
fredster45
fredster45 Sep. 10 at 12:39 PM
$SRPT let's see the srp-1002 data soon! Seedy19 posted the following on X: $LQDA cantor today suggesting IPF peak sales should be 5B not 2B , clearly they think it’s a bigger market than being modelled currently. This bodes well for $LQDA we will see it grind up from today imo
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:21 PM
G101SPM 9/2/2025, 7:34:32 AM $LQDA $30.69 bid. SELL/TAKE PROFITS ON 50% of net position. DAC (dollar average cost) $15.66 (5.23.25).
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:03 PM
G101SPM 8/12/2025, 6:51:18 AM $LQDA $23.55 bid. DAC (dollar average cost) $15.66 (5.23.25). CHANGE EXIT $35.00 (long term) from $25.00.
0 · Reply
EatingCatPoop
EatingCatPoop Sep. 9 at 2:22 PM
$LQDA I love it when we sell off right before we get good news 👀 lets get this last court case dropped
3 · Reply
G101SPM
G101SPM Sep. 9 at 1:12 PM
#ARCHIVES Transactions to September 5, 2025 from September 2, 2025. G101SPM 9/2/2025, 7:34:32 AM $LQDA $30.69 bid. SELL/TAKE PROFITS ON 50% of net position. DAC (dollar average cost) $15.66 (5.23.25). G101SPM 9/2/2025, 6:39:00 AM $BBIO $52.76 prior close. DAC (dollar average cost includes partial SELL at a profit to reduce costs). $27.91 / last $33.50 (3.6.25). CHANGE EXIT TO $70.00 FROM $55.00.
0 · Reply
NatesNotes
NatesNotes Sep. 9 at 3:46 AM
fwiw, abc, as we have seen as time has gone by, there are a lot of folks on the $MNKD stream who believe that how the stock of $LQDA trades somehow impacts the potential return they might see with their MNKD investment #thedupedest... but, of course, logic suggests that is just another false narrative served up for us by the folks who don't know much about investing in the biotech space, and those of us who actually know what we own don't bother worrying about the false narratives they serve up as part of their campaign! ;-) #InTheirOwnWords #factsmatter
2 · Reply
Latest News on LQDA
Liquidia Analysts Raise Their Forecasts Following Q2 Results

Aug 13, 2025, 2:51 PM EDT - 4 weeks ago

Liquidia Analysts Raise Their Forecasts Following Q2 Results


Why Is Liquidia Stock Trading Higher On Tuesday?

Aug 12, 2025, 2:25 PM EDT - 4 weeks ago

Why Is Liquidia Stock Trading Higher On Tuesday?


Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 12:43 PM EDT - 4 weeks ago

Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript


What Next For Liquidia After Launch?

Jun 30, 2025, 10:40 AM EDT - 2 months ago

What Next For Liquidia After Launch?


These Analysts Boost Their Forecasts On Liquidia

May 28, 2025, 11:08 AM EDT - 3 months ago

These Analysts Boost Their Forecasts On Liquidia


Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript

May 10, 2025, 9:29 PM EDT - 4 months ago

Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript


Arquitos Capital's Largest Holdings  For Q1 2025

Apr 30, 2025, 9:30 AM EDT - 4 months ago

Arquitos Capital's Largest Holdings  For Q1 2025


Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 11:56 AM EDT - 6 months ago

Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript


Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:40 PM EST - 10 months ago

Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript


MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 6:55 PM
Enter: $LQDA OCT 17 2025 $28 CALLS Buy in Price: $2.55 - $2.75 Take Profit: $2.93 Stop Bleeding: $2.24 ROI Potential: 15% Exit Within: 64 Minutes https://moneygroup.us/alerts
0 · Reply
clan
clan Sep. 13 at 9:45 AM
$LQDA Filling the gap. Sell. Short. Buy puts. $SPY people react.
0 · Reply
stocksmanagement
stocksmanagement Sep. 12 at 7:26 PM
$LQDA will re bullish
0 · Reply
BullRun4
BullRun4 Sep. 12 at 7:11 PM
$LQDA Yutrepia is the clear WINNER with Pulmonologist for patients with PH-ILD! Liquidia is growing their business at a super fast rate. Sales are going very strong and next filing will demonstrate how quickly they have taken control of that patient segment.
2 · Reply
fredster45
fredster45 Sep. 10 at 12:39 PM
$SRPT let's see the srp-1002 data soon! Seedy19 posted the following on X: $LQDA cantor today suggesting IPF peak sales should be 5B not 2B , clearly they think it’s a bigger market than being modelled currently. This bodes well for $LQDA we will see it grind up from today imo
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:21 PM
G101SPM 9/2/2025, 7:34:32 AM $LQDA $30.69 bid. SELL/TAKE PROFITS ON 50% of net position. DAC (dollar average cost) $15.66 (5.23.25).
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:03 PM
G101SPM 8/12/2025, 6:51:18 AM $LQDA $23.55 bid. DAC (dollar average cost) $15.66 (5.23.25). CHANGE EXIT $35.00 (long term) from $25.00.
0 · Reply
EatingCatPoop
EatingCatPoop Sep. 9 at 2:22 PM
$LQDA I love it when we sell off right before we get good news 👀 lets get this last court case dropped
3 · Reply
G101SPM
G101SPM Sep. 9 at 1:12 PM
#ARCHIVES Transactions to September 5, 2025 from September 2, 2025. G101SPM 9/2/2025, 7:34:32 AM $LQDA $30.69 bid. SELL/TAKE PROFITS ON 50% of net position. DAC (dollar average cost) $15.66 (5.23.25). G101SPM 9/2/2025, 6:39:00 AM $BBIO $52.76 prior close. DAC (dollar average cost includes partial SELL at a profit to reduce costs). $27.91 / last $33.50 (3.6.25). CHANGE EXIT TO $70.00 FROM $55.00.
0 · Reply
NatesNotes
NatesNotes Sep. 9 at 3:46 AM
fwiw, abc, as we have seen as time has gone by, there are a lot of folks on the $MNKD stream who believe that how the stock of $LQDA trades somehow impacts the potential return they might see with their MNKD investment #thedupedest... but, of course, logic suggests that is just another false narrative served up for us by the folks who don't know much about investing in the biotech space, and those of us who actually know what we own don't bother worrying about the false narratives they serve up as part of their campaign! ;-) #InTheirOwnWords #factsmatter
2 · Reply
MarketPro
MarketPro Sep. 8 at 8:24 PM
0 · Reply
JohnB72
JohnB72 Sep. 8 at 5:08 PM
$LQDA can someone comment how were yutrepia sales last week?
3 · Reply
grampslol
grampslol Sep. 8 at 5:07 PM
$MNKD we mustn't forget that $LQDA Yutrepia DPI is already a big hit in the IPF market space and is crushing it in PAH. Poor tyvaso dpi behind the 8 ball. $UTHR #afizzle
1 · Reply
MikeWazowski44
MikeWazowski44 Sep. 8 at 2:14 PM
$LQDA 🎯
1 · Reply
SteelerJon
SteelerJon Sep. 7 at 12:56 PM
$LQDA In the stronger adoption camp🏕️🏦🏦 https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lqda/liquidia/news/rapid-uptake-of-yutrepia-might-change-the-case-for-investing
1 · Reply
SteelerJon
SteelerJon Sep. 7 at 12:53 PM
$LQDA 😎🏦🏦 https://finance.yahoo.com/news/jefferies-highlights-yutrepia-market-edge-171411590.html
0 · Reply
BullRun4
BullRun4 Sep. 6 at 9:48 PM
$LQDA If patient preference is with Yutrepia prescribers will continue to grow even with those Tyvaso loyalist.
0 · Reply
speedrr
speedrr Sep. 6 at 5:59 PM
$LQDA more patients not happy with Tyvaso and moving to Yutrepia
0 · Reply
speedrr
speedrr Sep. 5 at 7:37 PM
$LQDA patients happier with Yutrpia
4 · Reply
speedrr
speedrr Sep. 5 at 3:29 PM
$LQDA $30 come on
0 · Reply
cmstripling
cmstripling Sep. 5 at 2:05 PM
$LQDA May take little bit but we'll clear $30.
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Sep. 5 at 4:55 AM
$LQDA is pushing in wave ((5)) of I within cycle from July 2025 low. A final leg may target 28.98+ before a corrective pullback in wave II unfolds in 3, 7 or 11 swingsm, which later provides swing buy opportunity. Details 👉 https://elliottwave-forecast.com/stock-market/liquidia-lqda-bullish-sequence-eyes-28-98-next-pullback/ #Elliottwave #stocks
0 · Reply